arly restoration of blood flow in the infarct-related artery (IRA) with consequent restitution of myocardial perfusion is the aim of treatment of patients with acute myocardial infarction (AMI). [1] [2] [3] [4] [5] A strategy of routine stent implantation during percutaneous coronary intervention (PCI) in AMI patients is the most immediate and reliable method for recanalizing the occluded artery, but the limitations of this strategy include distal embolism and a lower incidence of thrombolysis in myocardial infarction (TIMI) study grade 3 flow, compared with primary angioplasty alone. 6, 7 The no-reflow phenomenon, which is characterized by impaired myocardial perfusion despite reopening of the epicardial coronary artery, can occur during PCI in patients with AMI and is predictive of poor prognosis. [8] [9] [10] This phenomenon, when identified on an angiogram, is named 'angiographic no-reflow' and is defined as coronary antegrade flow reduction without mechanical obstruction: it occurs in 10-20% of patients with AMI despite reopening of the IRA by PCI. 6, 7, 9, 11 EmCirculation Journal Vol.68, August 2004 bolization of thrombus and plaque may play an important role in angiographic no-reflow. 12,13 Although thrombectomy before mechanical dilatation provides better angiographic epicardial coronary flow in AMI, it is still unclear whether this strategy could provide better myocardial perfusion. 14 A recent study demonstrated that the occlusive balloon type distal protection device (PercuSurge GuardWire; GW) reduced distal embolization during scheduled PCI for venous grafts, 15 but little is known about the effects of this device against no-reflow during emergency PCI in AMI patients. It is also unclear whether left ventricular (LV) function is preserved by PCI with GW protection. We hypothesized that primary stenting with GW protection could reduce angiographic no-reflow and preserve LV function.
undergoing thrombolytic therapy before PCI, (2) spontaneous restoration of coronary flow before PCI (initial angiography showed TIMI 2 or 3 flow), or (3) Killip class IV. Since September 1999, our routine strategy for AMI has been to recanalize the occluded vessel using an intracoronary thrombectomy catheter followed by primary stenting. Following approval of the distal protection device in Japan, we have routinely used this device in the setting of stenting. Patients were divided into 2 groups according to the time periods in which the 2 different therapeutic strategies were applied. The GW group comprised 42 consecutive patients treated by primary stenting after thrombectomy with GW protection, from June 1, 2002 to July 31, 2003 , and the control group comprised 30 consecutive patients treated by primary stenting after thrombectomy without GW protection, from Jan 1, 2001 to May 31, 2002 . Written informed consent was obtained from all patients.
Coronary Intervention
Patients were premedicated with aspirin (162 mg orally) and brought to the catheter laboratory. Unfractionated heparin (10,000 IU) was administered intravenously during the procedure.
GW Group Angioplasty was performed according to the following procedure.
(1) A conventional guidewire was advanced across the target lesion.
(2) An export catheter was advanced over the guidewire and the target lesion was aspirated.
(3) The conventional guidewire was exchanged for a 0.014-inch GW.
(4) The occlusion balloon at the GW tip was inflated to occlude distal flow prior to stent implantation.
(5) Stent implantation was performed in the standard manner.
(6) The export catheter was advanced and aspirated proximal to the occlusion balloon after stent implantation.
(7) The occlusion balloon was deflated.
Control Group Angioplasty was performed by primary stent implantation after thrombectomy using a Rescue thrombectomy catheter (SciMED/BSC, Inc) without a distal protection device.
In cases in which the thrombectomy devices could not be passed through the culprit lesion, predilation with a small sized balloon (1.5 or 2.0 mm) was performed. Intra-aortic balloon pumping (IABP) was indicated if (1) angiographic no-reflow occurred, (2) Killip class >2, or (3) cardiogenic shock developed during PCI. After PCI, standard medical therapy for AMI was commenced in both groups. None of the patients received glycoprotein IIa/IIIb inhibitors because these drugs were not approved for use in Japan.
Assessment of Coronary Flow and LV Function
Immediately after PCI, antegrade blood flow in the IRA and myocardial perfusion were evaluated according to the TIMI flow grade (TFG), the corrected TIMI frame counts (cTFC), and the myocardial blush grade (MBG) by 2 experienced investigators who were unaware of the other patient data. The TFG, cTFC, and MBG were assessed according to established definitions, and cTFC was based on the most common filming speed of 30 frames/s. [16] [17] [18] The angiographic no-reflow phenomenon was defined as a decrease in final TFG compared with TFG before stent implantation without evidence of spasm or dissection.
Left ventriculography and coronary angiography were performed immediately (acute phase) and 3 weeks (subacute phase) after PCI. LV end-diastolic volume index (LVEDVI) and LV end-systolic volume index (LVESVI) were measured using Simpson's rule, and the ejection fraction (EF) was calculated. Regional wall motion (RWM) abnormality in the LAD territory was determined by the center line method. 19 
Data Collection
The following data were obtained: age, gender, coronary risk factors, time from onset to revascularization (ischemic time), adjunctive medications, IABP use, stent size, stent length and maximum inflation pressure of stent implantation, and peak serum concentrations of CK, and CK myocardial fraction (CK-MB) were determined from blood samples obtained every 4 h following revascularization of the IRA.
Statistical Analysis
Continuous variables are presented as mean ± SEM and were compared using the unpaired Student's t-test. Categorical variables were compared using the chi-square analysis. Serial changes between the 2 groups were compared by analysis of variance (ANOVA: StatView 5.0, SAS Institute Inc). For all analyses, a p-value < 0.05 was defined as statistically significant.
Results
Of the 42 patients in the GW group, 35 (83.3%) had the GW device delivered correctly. In 7 patients (16.7%) GW delivery was not performed for the following reasons. In 2 patients the vessel diameters at the protection balloon site were less than 3 mm, which was the minimum diameter of the protection balloon was 3 mm (ie, it is necessary for the vessel diameter at the distal LAD to be >3 mm). In 3 patients, the operators were not experienced in the procedure. In 1 patient, the distal protection balloon deflated spontaneously during PCI and GW delivery was not electively performed in 1 patient with triple vessel disease.
The maximum occlusion time by inflation of the protection balloon was 6 min and the mean occlusion time was 3.8±0.8 min. Minor coronary dissections at the site of the protection balloon occurred in 2 patients, but no adjunctive intervention was required in either case. Table 1 shows the baseline characteristics of the subjects in the present study; age, gender, and risk factors were similar between the 2 groups. Several factors, including adjunctive medications, IABP use, and ischemic time, which are known to influence LV remodeling, were also similar between the 2 groups. The index of severity (including the Killip class), presence of collateral circulation, and the number of cases of single-vessel disease were also comparable. Seven patients (20%) in the GW group, and 9 patients (30%) in the control group were treated with predilation by a smaller sized balloon before stent implantation. Stent size, stent length, and maximum inflation pressure of stent implantation were similar between the 2 groups.
Baseline Characteristics

Coronary Flow After PCI
The results of TFG, cTFC, and MBG are shown in Table 2 : 31 patients (88.6%) in the GW group and 22 (73.3%) in the control group demonstrated TFG 3 after stent implantation; angiographic no-reflow occurred in 4 patients (11.4%) in the GW group and in 8 (26.7%) in the control group; cTFC values after stent implantation were significantly lower in the GW group than in the control group (27.5±2.3 vs 35.1±2.5, p=0.030); and 16 (45.7%) patients in the GW group and 6 (20.0%) patients in the control group exhibited MBG 3 after primary stenting (p=0.029).
Infarct Size, In-Hospital Cardiac Events, and LV Function
Peak CK concentrations were similar between the 2 groups; however, peak CK-MB concentrations were significantly lower in the GW group (326.6±41.5 vs 454.9± 46.2 mg/dl, p=0.043). In both groups, there were no cardiac events such as cardiac death, myocardial re-infarction and target vessel revascularization during the hospital stay and pre-discharge coronary angiography revealed no restenosis of the target lesion in any of the patients. The LVEF, LVEDVI, LVESVI, and RWM abnormalities in the LAD territory are shown in Table 3 : there were no significant differences in these parameters in the acute phase. However, RWM abnormalities in the subacute phase were significantly higher in the GW group than in the control group (-2.03±0.14 vs -2.51±0.14 SD/chord, p=0.018). Serial changes in these variables, which were compared using ANOVA, are shown in Fig 1. Serial changes in LVEF (+4.6±1.2 vs -1.1±1.5%, p=0.004), LVESVI (+0.5±2.4 vs +9.0±2.7 ml/m 2 , p=0.023), and RWM abnormalities (+1.0± 0.1 vs +0.6±0.1 SD/chord, p=0.014) had improved significantly in the GW group over the control group.
Discussion
The present study indicates that primary stenting with distal protection in patients with AMI can preserve not only epicardial coronary flow but also myocardial perfusion and LV function. Although primary stenting is the most reliable strategy, the no-reflow phenomenon does occur in some patients. Investigators have reported the management of no-reflow, [20] [21] [22] [23] but few preventive therapies for no-reflow in AMI have been described. Recently, Limbruno et al reported the effectiveness and safety of the non-occlusive filter type distal protection device (FilterWire-Ex ® ) during PCI in AMI caused by native coronary obstruction; 24 however, the effects of the filter type protection device for LV function remain uncertain because of the variation in IRAs in that study. Furthermore, there are no data on the effects of the occlusive balloon type distal protection device used in the present study (PercuSurge GuardWire ® ) during PCI of native coronary arteries. The present study is the first to demonstrate the effects of GW protection on LV function in patients with anterior AMI. 
Coronary Flow After PCI
Restoration of excellent epicardial coronary flow improves the prognosis of AMI. [1] [2] [3] 6 In the present study, the final cTFC after stenting was lower in the GW group than in the control group. Gibson et al reported that the cTFC is an objective, reproducible, and quantitative index of coronary flow that allows prediction of prognosis. 17, 25 Similarly, primary stenting with GW protection was associated with a higher occurrence of TFG 3. Our results indicate that primary stenting with GW protection is better at restoring epicardial coronary flow.
The aim of PCI in AMI is the reperfusion of infarcted myocardium as well as restoration of the antegrade coronary blood flow. The MBG after PCI is a simple and reliable parameter of myocardial perfusion, and is a predictor of long-term prognosis. 18, 26, 27 In the present study, the GW group showed higher rates of MBG 3 (45.7 vs 20.0%) and greater improvement in LV function. In past studies, only 20-30% of patients with AMI treated by PCI have demonstrated MBG 3, 26,27 so our findings suggest that primary stenting with GW protection can more effectively restore myocardial perfusion than conventional strategies, including thrombectomy.
The angiographic no-reflow phenomenon, which also implies impairment of myocardial perfusion, is known to occurred in 5-25% patients with AMI after PCI and is indicative of poor prognosis. 6, 9, 28 In the present study, the rate of angiographic no-reflow had the tendency, although not significantly, to be lower in the GW group than in the control group (11.4 vs 26.7%). Some investigators have suggested that embolization of thrombus and plaque play an important role in angiographic no-reflow. 13, 24, 29 The distal protection device removes these materials by aspiration before restoration of antegrade flow. The no-reflow phenomenon often occurs after stent implantation, 6,7 so the strategy of thrombectomy alone before stent implantation cannot prevent embolization of these materials. PCI with a distal protection device is considered to be the only preventative therapy for the no-reflow phenomenon by embolization.
The no-reflow phenomenon is known to be caused by multiple factors such as microvascular spasm, myocardial edema, endothelial dysfunction, and embolization of thrombus and plaque. PCI with the GW device could not prevent the no-reflow phenomenon completely in our study, and one of the reasons might be that myocardial or/and microvascular damage had already developed at the time of reperfusion because the mean ischemic time was more than 6 h in both groups.
LV Function and Remodeling
LV function and remodeling after AMI is considered to be influenced by many factors including no-reflow, 9 ischemic time, infarct size, wall stress, and medications such as angiotensin converting enzyme inhibitors, -blockers, nicorandil 30, 31 and human atrial natriuretic peptide. 32, 33 Several recent trials have suggested that nicorandil and human atrial natriuretic peptide preserve LV function by reducing no-reflow phenomenon, so our anterior AMI patients have been treated routinely with these drugs since 2000 if patient's blood pressure will allow it. These drugs might have affected coronary flow and the recovery of LV function, but the clinical baseline characteristics and medications after stenting, except for coronary flow and MBG after stenting, were not significantly different between the 2 groups. Additionally, we enrolled only those patients in whom the culprit lesion was the proximal LAD, in order to assess the effects of primary stenting with GW protection on LV function. Under such a clinical setting, the enzymatic infarction size (ie, peak CK-MB concentration) was lower in the GW group than in the control group, which indicates that PCI with GW protection can diminish LV damage. Improvements in LVEF, LVEDVI, and RWM abnormalities were significantly higher in the GW group than in the control group. Therefore, primary stenting with GW protection in AMI appears to reduce the progression of LV dilatation by reduction of the no-reflow phenomenon and superior perfusion of the infarcted myocardium.
Study Limitations
This study was retrospective and non-randomized because the GW device had not been approved for use in Japan prior to May, 2002. However, we believe it can still evaluate the effect of the GW device, because baseline clinical characteristics, except for PCI strategy, were similar between the 2 groups. Second, the present study population was small and from one center. Third, we enrolled only AMI patients with a proximal LAD occlusion in order to evaluate the effect of the GW device on LV function, thus we did not assess the effect of this device on other vessels. Fourth, the safety and cost effectiveness were not assessed and fifth, we excluded AMI patients who received thrombolytic therapy, and none received glycoprotein IIa/IIIb inhibitors, so we could not assess the effects of these drugs on the no-reflow phenomenon. These limitations suggest the need for a large clinical trial to determine whether PCI with the GW device should be recommended for all patients with AMI.
Conclusions
Angiographic no-reflow by embolization may be prevented by the distal protection device used in this study. Primary stenting with GW protection can preserve LV function by restoring better epicardial coronary flow and perfusion of the infarcted myocardium.
